Insider Buying: ADMA Biologics, Inc. (NASDAQ:ADMA) Director Buys $482,300.00 in Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) Director Jerrold B. Grossman purchased 130,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The shares were bought at an average price of $3.71 per share, with a total value of $482,300.00. Following the completion of the transaction, the director now owns 443,265 shares of the company’s stock, valued at $1,644,513.15. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

ADMA Biologics Price Performance

Shares of ADMA opened at $3.89 on Friday. ADMA Biologics, Inc. has a fifty-two week low of $2.24 and a fifty-two week high of $4.65. The firm’s 50 day moving average price is $3.90 and its 200 day moving average price is $3.69. The company has a market cap of $874.88 million, a P/E ratio of -19.45 and a beta of 0.79. The company has a quick ratio of 2.49, a current ratio of 6.35 and a debt-to-equity ratio of 1.03.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). ADMA Biologics had a negative net margin of 19.36% and a negative return on equity of 27.55%. The firm had revenue of $60.12 million for the quarter, compared to the consensus estimate of $55.45 million. During the same period in the prior year, the firm earned ($0.07) EPS. On average, research analysts forecast that ADMA Biologics, Inc. will post -0.06 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Large investors have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new stake in shares of ADMA Biologics in the 4th quarter valued at approximately $653,000. Pictet Asset Management SA increased its position in shares of ADMA Biologics by 46.4% in the 1st quarter. Pictet Asset Management SA now owns 32,474 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 10,295 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of ADMA Biologics by 391.9% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 814,836 shares of the biotechnology company’s stock valued at $3,162,000 after purchasing an additional 649,198 shares during the last quarter. Inspire Investing LLC purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $540,000. Finally, EWG Elevate Inc. purchased a new stake in shares of ADMA Biologics in the 1st quarter valued at approximately $331,000. 73.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of recent analyst reports. Mizuho lifted their price target on shares of ADMA Biologics from $6.00 to $7.00 in a research report on Thursday, August 10th. StockNews.com upgraded shares of ADMA Biologics from a “sell” rating to a “hold” rating in a research report on Saturday. Raymond James lifted their price target on shares of ADMA Biologics from $5.00 to $6.00 and gave the company a “strong-buy” rating in a research report on Thursday, August 10th. HC Wainwright lifted their price target on shares of ADMA Biologics from $4.50 to $5.00 and gave the company a “buy” rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald lifted their price objective on shares of ADMA Biologics from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Thursday, August 10th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.00.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.